励晶太平洋(00575) - 2025 - 中期财报

CONTENTS 目錄 • A reduced loss attributable to shareholders of the Company of approximately US$2.22 million, which was mainly attributable to the Group's operating and R&D expenses of approximately US$2.25 million. • In respect of the progress being made with Senstend™ in the PRC, the main objective remains for Wanbang Biopharmaceutical to obtain marketing approval by the end of 2025, with first commercial launch projected to start in Q1 2026. If the NMPA grants an import licence for Senstend™, US$5 million ( ...